DIAGNOSTIC TEST KITS COMPRISING PRIMARILY

Brand Owner (click to sort) Address Description
CITE SEMI-QUANT IDEXX CORP. 100 FORE STREET PORTLAND ME 04101 DIAGNOSTIC TEST KITS COMPRISING PRIMARILY CHEMICAL REAGENTS FOR IN VITRO VETERINARY USE;
FUJIREBIO FUJIREBIO INC. 1-1, Nishishinjuku 2-chome, Shinjuku-ku Tokyo 163-0410 Japan diagnostic test kits comprising primarily diagnostic reagents for medical use;
FUJIREBIO FUJIREBIO KABUSHIKI KAISHA (JAPAN CORPORATION) 62-5, NIHONBASHI-HAMACHO 2-CHOME CHUO-KU Tokyo Japan diagnostic test kits comprising primarily diagnostic reagents for medical use;
GONO GEN New Horizons Diagnostic Company 7194 Oakland Mills Rd. Columbia MD 21045 Diagnostic Test Kits Comprising Primarily Reagents for In Vitro Testing for Niesseria Gonorrheae;
MEDMIRA MedMira Laboratories Inc. 155 Chain Lake Drive, Suite 1 Halifax, Nova Scotia B3S1B3 Canada DIAGNOSTIC TEST KITS COMPRISING PRIMARILY OF REAGENTS, TEST SUBSTRATES AND SAMPLE COLLECTION VESSELS FOR USE IN DETECTING THE PRESENCE OF ANTIGENS, ANTIBODIES AND INFECTIOUS AGENTS FOR CLINICAL AND MEDICAL USE;MEDICAL MIRA;DIAGNOSTIC TEST KITS COMPRISING PRIMARILY OF REAGENTS, TEST SUBSTRATES AND SAMPLE COLLECTION VESSELS FOR USE IN DETECTING THE PRESENCE OF ANTIGENS, ANTIBODIES AND INFECTIOUS AGENTS FOR SCIENTIFIC AND RESEARCH USE;
STACPAK IDEXX CORP. 100 FORE STREET PORTLAND ME 04101 DIAGNOSTIC TEST KITS COMPRISING PRIMARILY CHEMICAL REAGENTS FOR IN VITRO VETERINARY USE;STACK PACK;
SUCCEED Freedom Health 65 Aurora Industrial Parkway Aurora OH 44202 diagnostic test kits comprising primarily preparations in the nature of cell testing kits to detect the presence of ulcers in animals;Color is not claimed as a feature of the mark.;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. A new gene-MN-and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes. The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression, and polymerase chain reaction (PCR) assays to detect genetic rearrangements.